STUDY OF THE PROBLEM OF HYPERALUMINAEMIA IN CHILDREN WITH CHRONIC RENAL FAILURE

Thesis

Submitted for partial fulfillment of
Master Degree in **Paediatrics**

By

Sherif Mohamed El Desouky Ibrahim

M.B.,B.Ch., Ain Shams University

Supervised by

Prof. Dr. Farida Ahmed Farid

Professor of Paediatrics

Faculty of Medicine, Ain Shams University

Prof. Dr. Akeela Kaisser Khella

Professor & Head of Community Medicine Dept.

Faculty of Medicine, Ain Shams University

Dr. Zeinab Awad El-Sayed

Assist. Prof. of Paediatrics

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

1997



بسم الله الرحمن الرحيم

وقل رب زدني علما

صدق الله العظيم (طه ١١٤)

Acknowledgment

First and foremost, I thank ***God*** Almighty, the Beneficent and the Most Merciful.

I wish to express my sincere gratitude and appreciation to ***Prof. Dr. Farida Ahmed Farid***, Professor of Pediatrics, Ain Shams University, for her generous help, emminent supervision and careful review of all the details of this work.

I am extremely grateful to ***Dr. Zeinab Awad El-Sayed,*** Ass. Prof. of Pediatrics, Ain Shams University, for her continuous guidance, kind supervision and assistance offered throughout the entire work.

I want to express my deepest appreciation to ***Prof. Dr. Akila K. Khella***, Professor and Head of Community Medicine Department, Ain Shams University.

I would like to thank ***Prof. Dr. Ahmed Abd El Karim,*** Professor of Public Health Ain Shams University, for his remarkable help and excellent experience in the practical part of this work.

Last, but certainly not least, I am grateful to everyone who participated in the evaluation of this work.

Sherif El Desouky

CONTENTS

	Page
Introduction	1
Aim of the work	3
Review of Literature	4
• Sources of aluminum	11
• Measurement of serum aluminum	16
• Toxicity of aluminum	18
• The nervous system and aluminum	19
• aluminum bone disease	24
• Anemia	28
• Aluminum and other disorders	31
• Diagnosis of aluminum overload	33
• Management of aluminum toxicity	36
Subjects and Methods	44
Results	50
Discussion	74
Summary and Conclusions	84
Recommendations	88
References	89
Arabic Summary	

LIST OF TABLES

Tab. No.	Title	Page
1	Factors affecting aluminum absorption	7
2	Estimate of aluminum intake and absorption from various sources	8
3	Percent of elemental aluminum contained in aluminum-containing drugs	14
4	List of aluminum levels of commonly used intravenous solutions	14
5	Progression of neurologic changes in children developing the encephalopathy of progressive renal failure	21
6	Interpretation and normal values of serum aluminum	34
7	Hazards of deferioxamine administration	42
8	Clinical data of chronic renal failure patients	51
9	laboratory data of chronic renal failure patients	52
10	Clinical and laboratory data of the control group	53
11	Serum aluminum levels in the groups of the study	54

12	comparison between CRF patients and control group as regards laboratory parameters	56
13	Aluminum levels in different water samples	57
14	Correlation betweenserum aluminum before DFO test and other parameters of CRF patients	70

LIST OF FIGURES

Fig. No.	Title	Page
1	Monitoring and diagnosis of aluminum accumulation and toxicity	37
2	comparison between mean level of serum aluminum in patients with Hb <7 gm% versus those with Hb >7 gm% (before and after DFO test)	58
3	Comparison between mean level of serum aluminum in CRF patients with frequency of blood transfusion ≥ 1month versus < 1 month (before and after DFO test)	59
4	comparison between mean levels of serum aluminum in CRF patients with and without EPO treatment (before and after DFO test)	60
5	Mean levels of Hb% in CRF patients with and without EPO treatment	61
6	Correlation between MCV and serum aluminum (before DFO test) in CRF patients	62
7	Correlation between Hb% and serum aluminum (before DFO test) in CRF patients	63

8	Comparison between mean levels of serum aluminum in CRF patients with and without orthopedic manifestations (before and after DFO test)	64
9	comparison between mean levels of serum aluminum in CRF patients with normal PTH <55 pgm/ml versus PTH level >55 pgm/ml before and after DFO test	65
10	Correlation between PTH and serum aluminum (before DFO test) in CRF patients	66
11	Correlation between serum alkaline phosphatase and serum aluminum (before DFO test) in CRF patients	67
12	Comparison between mean levels of serum aluminum in CRF patients with and without neuropsychiatric manifestations (before and after DFO test)	68
13	Correlation between duration of disease (months) and serum aluminum (before DFO test) in the patients group	71
14	Correlation between glumerular filtration rate and serum aluminum (before DFO test) in the patients group	72
15	Correlation between serum ferritin and serum aluminum (before DFO test) in the patients group	73

Introduction and Aim of the work